Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey-Reference-Cited by-同舟云学术

Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey

Published:2024-01 Issue:1 Volume:17 Page:
ISSN:1941-7713
Container-title:Circulation: Cardiovascular Quality and Outcomes
language:en
Short-container-title:Circ: Cardiovascular Quality and Outcomes

Author:

Lu Yuan¹²³^ORCID,Liu Yuntian¹^ORCID,Jastreboff Ania M.³⁴⁵^ORCID,Khera Rohan¹²^ORCID,Ndumele Chima D.⁶,Rodriguez Fatima⁷^ORCID,Watson Karol E.⁸^ORCID,Krumholz Harlan M.¹²³⁶^ORCID

Affiliation:

1. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, CT (Y. Lu, Y. Liu, R.K., H.M.K.).

2. Section of Cardiovascular Medicine, Department of Internal Medicine (Y. Lu, R.K., H.M.K.), Yale School of Medicine, New Haven, CT.

3. Yale Obesity Research Center (Y-Weight) (Y. Lu, A.M.J., H.M.K.), Yale School of Medicine, New Haven, CT.

4. Department of Medicine (Endocrinology and Metabolism) (A.M.J.), Yale School of Medicine, New Haven, CT.

5. Department of Pediatrics (Pediatric Endocrinology) (A.M.J.), Yale School of Medicine, New Haven, CT.

6. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT (C.D.N., H.M.K.).

7. Division of Cardiovascular Medicine, School of Medicine, Stanford University, CA (F.R.).

8. David Geffen School of Medicine, University of California, Los Angeles (K.E.W.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

2. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design

3. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

4. US Food and Drug Administration. FDA approves new drug treatment for chronic weight management first since 2014. Accessed October 17 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014

5. Centers for Disease Control and Prevention. US National Health and Nutrition Examination Survey. Accessed April 17 2023. http://www.cdc.gov/nchs/nhanes.htm

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial;American Heart Journal;2024-10

2. National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US;JAMA Network Open;2024-07-03